AU2016302047B2 - Muscarinic agonists - Google Patents
Muscarinic agonists Download PDFInfo
- Publication number
- AU2016302047B2 AU2016302047B2 AU2016302047A AU2016302047A AU2016302047B2 AU 2016302047 B2 AU2016302047 B2 AU 2016302047B2 AU 2016302047 A AU2016302047 A AU 2016302047A AU 2016302047 A AU2016302047 A AU 2016302047A AU 2016302047 B2 AU2016302047 B2 AU 2016302047B2
- Authority
- AU
- Australia
- Prior art keywords
- compound according
- hydrocarbon group
- carboxylate
- ethyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1513740.9A GB201513740D0 (en) | 2015-08-03 | 2015-08-03 | Muscarinic agonist |
| GB1513740.9 | 2015-08-03 | ||
| PCT/GB2016/052384 WO2017021728A1 (en) | 2015-08-03 | 2016-08-03 | Muscarinic agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2016302047A1 AU2016302047A1 (en) | 2018-02-15 |
| AU2016302047A8 AU2016302047A8 (en) | 2018-03-08 |
| AU2016302047B2 true AU2016302047B2 (en) | 2020-09-10 |
Family
ID=54063147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016302047A Active AU2016302047B2 (en) | 2015-08-03 | 2016-08-03 | Muscarinic agonists |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10548884B2 (enExample) |
| EP (1) | EP3331528B1 (enExample) |
| JP (1) | JP6847093B2 (enExample) |
| CN (1) | CN107949384B (enExample) |
| AU (1) | AU2016302047B2 (enExample) |
| CA (1) | CA2994143C (enExample) |
| DK (1) | DK3331528T3 (enExample) |
| ES (1) | ES2894855T3 (enExample) |
| GB (1) | GB201513740D0 (enExample) |
| WO (1) | WO2017021728A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2619829T3 (es) | 2011-11-18 | 2017-06-27 | Heptares Therapeutics Limited | Agonistas del receptor muscarínico M1 |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| EP3394061B1 (en) | 2015-12-23 | 2020-03-11 | Merck Sharp & Dohme Corp. | 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| EP3651762B1 (en) | 2017-07-12 | 2024-07-03 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| JP7270989B2 (ja) | 2017-10-20 | 2023-05-11 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| EP3732163A4 (en) * | 2017-12-20 | 2021-07-14 | Vanderbilt University | MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS |
| EP3768669B1 (en) * | 2018-03-23 | 2023-01-25 | Pfizer Inc. | Piperazine azaspiro derivaves |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| JP7697933B2 (ja) * | 2019-09-25 | 2025-06-24 | オンコアレンディ セラピューティクス エス．エー． | ５－（４－（（２ｓ，５ｓ）－５－（４－クロロベンジル）－２－メチルモルホリノ）ピペリジン－１－イル）－１ｈ－１，２，４－トリアゾール－３－アミンの製造プロセス |
| UY38906A (es) * | 2019-10-09 | 2021-05-31 | Novartis Ag | Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos |
| PH12022550860A1 (en) * | 2019-10-09 | 2023-06-14 | Novartis Ag | 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists |
| US12486250B2 (en) | 2019-12-06 | 2025-12-02 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| TWI889751B (zh) * | 2020-02-05 | 2025-07-11 | 美商紐羅克里生物科學有限公司 | 蕈毒受體4拮抗劑及使用方法 |
| US20250064833A1 (en) | 2021-12-13 | 2025-02-27 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| KR20260046441A (ko) * | 2023-08-03 | 2026-04-07 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 합성 방법 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014045031A1 (en) * | 2012-09-18 | 2014-03-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2008137583A (ru) | 2006-02-22 | 2010-03-27 | Вертекс Фармасьютикалз Инкорпорейшн (Us) | Спиропиперидины в качестве модуляторов мускариновых рецепторов |
| US8003660B2 (en) | 2006-02-22 | 2011-08-23 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| AU2009309988A1 (en) | 2008-10-29 | 2010-05-06 | Grunenthal Gmbh | Substituted spiroamines |
| FR2945531A1 (fr) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| ES2619829T3 (es) | 2011-11-18 | 2017-06-27 | Heptares Therapeutics Limited | Agonistas del receptor muscarínico M1 |
| US9593106B2 (en) * | 2013-02-07 | 2017-03-14 | Heptares Therapeutics Limited | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists |
| RU2685230C2 (ru) * | 2014-02-06 | 2019-04-17 | Хептарес Терапьютикс Лимитед | Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов |
| GB201504675D0 (en) * | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
-
2015
- 2015-08-03 GB GBGB1513740.9A patent/GB201513740D0/en not_active Ceased
-
2016
- 2016-08-03 US US15/749,743 patent/US10548884B2/en active Active
- 2016-08-03 WO PCT/GB2016/052384 patent/WO2017021728A1/en not_active Ceased
- 2016-08-03 JP JP2018504993A patent/JP6847093B2/ja active Active
- 2016-08-03 ES ES16750221T patent/ES2894855T3/es active Active
- 2016-08-03 DK DK16750221.0T patent/DK3331528T3/da active
- 2016-08-03 AU AU2016302047A patent/AU2016302047B2/en active Active
- 2016-08-03 CA CA2994143A patent/CA2994143C/en active Active
- 2016-08-03 CN CN201680045225.6A patent/CN107949384B/zh active Active
- 2016-08-03 EP EP16750221.0A patent/EP3331528B1/en active Active
-
2019
- 2019-12-27 US US16/728,762 patent/US11324738B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014045031A1 (en) * | 2012-09-18 | 2014-03-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200129496A1 (en) | 2020-04-30 |
| WO2017021728A1 (en) | 2017-02-09 |
| AU2016302047A1 (en) | 2018-02-15 |
| US10548884B2 (en) | 2020-02-04 |
| CN107949384B (zh) | 2025-02-28 |
| CA2994143A1 (en) | 2017-02-09 |
| WO2017021728A9 (en) | 2017-04-27 |
| EP3331528B1 (en) | 2021-09-29 |
| US11324738B2 (en) | 2022-05-10 |
| EP3331528A1 (en) | 2018-06-13 |
| JP2018522034A (ja) | 2018-08-09 |
| JP6847093B2 (ja) | 2021-03-24 |
| ES2894855T3 (es) | 2022-02-16 |
| CA2994143C (en) | 2023-09-26 |
| US20180228791A1 (en) | 2018-08-16 |
| CN107949384A (zh) | 2018-04-20 |
| GB201513740D0 (en) | 2015-09-16 |
| DK3331528T3 (da) | 2021-10-25 |
| HK1250139A1 (en) | 2018-11-30 |
| AU2016302047A8 (en) | 2018-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11324738B2 (en) | Muscarinic agonists | |
| JP7652832B2 (ja) | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 | |
| US12024499B2 (en) | Muscarinic agonists | |
| HK1250139B (en) | Muscarinic agonists | |
| HK40114593A (en) | Pharmaceutical compounds | |
| HK1250138B (en) | Muscarinic agonists | |
| HK1231382A1 (en) | Muscarinic receptor agonists | |
| HK1231382B (en) | Muscarinic receptor agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH | Corrigenda |
Free format text: IN VOL 32 , NO 6 , PAGE(S) 840 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME HEPTARES THERAPEUTICS LIMTED, APPLICATION NO. 2016302047, UNDER INID (71) CORRECT THE APPLICANT NAME TO HEPTARES THERAPEUTICS LIMITED |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| HB | Alteration of name in register |
Owner name: NXERA PHARMA UK LIMITED Free format text: FORMER NAME(S): HEPTARES THERAPEUTICS LIMITED |